



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

**Oversight Committee Meeting Minutes
August 18, 2021**

NOTE: CPRIT conducted this meeting by videoconference in accordance with Governor Abbott's suspension of various provisions requiring government officials to be physically present at a specified meeting location. Unless the information is confidential, the reports, presentations, and grant award information referenced in the minutes are available in the "Oversight Committee Board Packet" section for the corresponding meeting date at <http://ocmeetings.cprit.texas.gov>.

Call to Order – Agenda Item 1

With a quorum present, Presiding Officer Dee Margo called the meeting to order at 9:04 a.m.

Roll Call/Excused Absences – Agenda Item 2

Committee Members Present

David Cummings, M.D.

Ambrosio Hernandez, M.D. (Dr. Hernandez joined after the meeting convened, as noted)

Donald (Dee) Margo

Will Montgomery

Mahendra Patel, M.D. (Dr. Patel joined after the meeting convened, as noted)

Cindy Barberio Payne

Bill Rice, M.D.

Craig Rosenfeld, M.D.

Adoption of Minutes from the May 19, 2021, Meeting – Agenda Item 3 – Tab 1

MOTION:

On a motion by Dr. Rice and seconded by Mr. Montgomery, the Oversight Committee unanimously voted to approve the minutes of the May 19, 2021, Oversight Committee meeting as presented.

Public Comment – Agenda Item 4

There were no public comments.

Chief Executive Officer Report – Agenda Item 5, Tab 2

Presiding Officer Margo recognized Mr. Roberts to present the Chief Executive Officer's Report. Mr. Roberts reported that CPRIT has sufficient funds to cover all proposed awards considered by the Oversight Committee today. He highlighted the 241 stellar recruits brought to Texas institutions of higher education since 2009. He noted that if the Oversight Committee approves the 12 proposed

recruitment awards today and each candidate accepts their award, CPRIT will achieve the milestone 250 CPRIT Scholars recruited to Texas.

There were no questions for Mr. Roberts.

Presiding Officer Margo noted for the record that Dr. Patel joined the meeting at 9:10 a.m.

Chief Compliance Officer Report and Compliance Certification for the Proposed Grant Awards – Agenda Item 6, Tab 3

Presiding Officer Margo recognized Chief Compliance Officer Vince Burgess to present the Compliance Report and Compliance Certification of Grant Award Process. Mr. Burgess updated members on the compliance program activities for the past quarter. He concluded his report with an update on the FY 2022 Grantee Risk Assessment and Monitoring Plan and noted that he will share additional details at the Oversight Committee meeting in November.

An Oversight Committee member asked about potential matching errors that occurred prior to the recent matching enhancements. Mr. Burgess explained that before the enhancements, CPRIT performed several ad hoc and onsite reviews that included sampling of the matching expenditures; as a result, he felt that implementing a 100% match expenditure review was prudent.

Mr. Burgess certified the review process for the proposed academic research, prevention and product development research grant awards, confirming that the proposed awards and review process complied with all applicable state and agency requirements.

Chief Scientific Officer Report and Grant Award Recommendations – Agenda Item 7, Tab 4

Presiding Officer Margo recognized Chief Scientific Officer Dr. Jim Willson to present the academic research program update and award recommendations. Presiding Officer Margo also noted for the record that Dr. Ambrosio joined the meeting at 9:26 a.m.

Dr. Willson directed members to Table 1 on page 6 of the Proposed Grant Award Book, which displayed the Scientific Review Council's (SRC) and PIC recommendations for the FY 2021.2 review cycle and recruitment cycles 2021.10, 2021.11 and 2021.12. The proposed recommendations include 62 awards from eight grant mechanisms totaling \$103,416,042.

He noted that two institutions recommended for awards, Southern Methodist University and The University of Texas Rio Grande Valley, are first-time CPRIT awardees.

Dr. Willson presented an overview of the eight academic research slates. He explained that CPRIT introduced three new RFAs in the FY 2021.2 cycle and provided a summary of each new mechanism: Texas Regional Excellence in Cancer Awards; Clinical Trials Network Awards; and Texas Clinical Trials Participation Awards.

FY 2021 Cycle 2 Proposed Academic Research Grant Awards

Rank	ID	Grant	Score	Application Title	PI	Organization	Budget
1	RP210227	CFSA	1.0	Proteomics and Metabolomics Core Facility	Edwards, Dean	Baylor College of Medicine	\$3,977,681
2	RP210176	ECI	1.0	CPRIT Early Clinical Investigator Award: Moran Amit	Draetta, Gulio	The University of Texas M. D. Anderson Cancer Center	\$1,499,042
3	RP210208	CFSA	1.1	Center for Innovative Drug Discovery: Expansion of a Highly Productive Shared Cancer Drug Discovery Resource for Texas	McHardy, Stanton	The University of Texas at San Antonio	\$3,087,131
4	RP210143	TCTPA	1.5	Dan L. Duncan Comprehensive Cancer Center Harris Health Clinical Trials Financial Support Project	Mims, Martha	Baylor College of Medicine	\$1,500,000
5	RP210165	HIHRRRA	1.6	Rapid Point-of-Care Detection of Ovarian Cancer Biomarkers Using a Common Thermometer for Low-Resource Settings	Li, Xiujun (James)	The University of Texas at El Paso	\$249,999
6	RP210115	TCTPA	1.7	Enhancing Access to and Diversity in Cancer Clinical Trials Through a Financial Reimbursement and Outreach Program	Gerber, David	The University of Texas Southwestern Medical Center	\$1,499,327
7	RP210159	ECI	1.8	CPRIT Early Clinical Investigator Award: Carl Gay	Draetta, Gulio	The University of Texas M. D. Anderson Cancer Center	\$1,499,997
8	RP210088	CFSA	1.9	Targeted Therapeutic Drug Discovery and Development Program	Dalby, Kevin	The University of Texas at Austin	\$3,989,441
9	RP210205	HIHRRRA	1.9	Cytokine Factories for the Treatment of Mesothelioma	Veisoh, Omid	Rice University	\$250,000
10	RP210173	HIHRRRA	1.9	Multiplex CRISPR Genetic Modeling of Polypharmacology for Precision Medicine	Hart, Travis	The University of Texas M. D. Anderson Cancer Center	\$250,000
11	RP210108	CFSA	2.0	The GCC Microphysiological Lead Optimization and Toxicity Screening Facility	Stephan, Clifford	Texas A&M University System Health Science Center	\$3,973,083
12	RP210144	HIHRRRA	2.0	Leveraging Glioma Stem Cell Electrophysiology for Therapy	Rostomily, Robert	The Methodist Hospital Research Institute	\$248,028
13	RP210168	HIHRRRA	2.0	Overcoming Myeloma Resistance to Proteasome Inhibitors	Yi, Qing	The Methodist Hospital Research Institute	\$250,000
14	RP210062	HIHRRRA	2.0	Protein Degradation of CDK9 for Treatment of Drug-Resistant Mantle Cell Lymphoma	Zhou, Jia	The University of Texas Medical Branch at Galveston	\$250,000

15	RP210154	TREC	2.0	Texas Regional Excellence in Cancer Developmental Therapeutics Center at TTUHSC	Reynolds, Charles	Texas Tech University Health Sciences Center	\$5,999,936
16	RP210073	HIHRRRA	2.1	Identification of Collateral Lethal and Synthetic Lethal Targets in Pancreatic and Colorectal Cancers	DePinho, Ronald	The University of Texas M. D. Anderson Cancer Center	\$249,994
17	RP210111	HIHRRRA	2.1	Single-Cell Proteomics to Dissect Intratumor Heterogeneity	Pan, Sheng	The University of Texas Health Science Center at Houston	\$250,000
18	RP210134	HIHRRRA	2.2	High-Throughput Discovery of Anticancer Protein Degradors	Tambar, Uttam	The University of Texas Southwestern Medical Center	\$250,000
19	RP210116	CFSA	2.3	The Genetic Design and Engineering Center (GDEC): A CPRIT Core Facility	Bao, Gang	Rice University	\$4,000,000
20	RP210158	HIHRRRA	2.3	Improving CAR T-Cell Therapy of T-ALL by Cotargeting Additional Antigens	Mamonkin, Maksim	Baylor College of Medicine	\$250,000
21	RP210206	HIHRRRA	2.4	Novel Tumor-Specific Bioactive Nanoparticles for Cancer Therapy	Nguyen, Kytai	The University of Texas at Arlington	\$249,999
22	RP210180	CFSA	2.5	Integrated Cancer Research Core (ICRC)	Chauhan, Subhash	The University of Texas Rio Grande Valley	*\$2,525,000
23	RP210126	CFSA	2.5	High-Parameter Analysis, Sorting, and Imaging Flow Cytometry Shared Resource	Berton, Michael	The University of Texas Health Science Center at San Antonio	\$3,645,500
24	RP210122	CTNA	2.5	Building a Clinical Trial Network for Texas Community Affiliates	Overman, Michael	The University of Texas M. D. Anderson Cancer Center	\$3,000,000
25	RP210164	ECI	2.5	Early Clinical Investigator Award: William Kelly	Hromas, Robert	The University of Texas Health Science Center at San Antonio	\$1,499,985
26	RP210140	ECI	2.6	Targeting Altered Metabolism in IDH-Mutant Glioma	Arteaga, Carlos	The University of Texas Southwestern Medical Center	\$1,500,000
27	RP210089	HIHRRRA	2.6	Dissecting Therapeutic Immunomodulation of Gut Microbiome on Colorectal Cancer	Kim, Hyun Jung	The University of Texas at Austin	\$250,000
28	RP210079	HIHRRRA	2.7	Targeting Mitochondrial NAD+ in Leukemias	Cambronne, Xiaolu	The University of Texas at Austin	\$250,000
29	RP210236	HIHRRRA	2.7	Magnetomechanical Modulation of Blood-Brain Barrier Permeability	Qin, Zhenpeng	The University of Texas at Dallas	\$250,000

30	RP210234	ECI	2.7	Targeting Src Homology-2 Domain-Containing Phosphatase to Overcome Resistance to Immune Checkpoint Blockade in Pancreatic Ductal Adenocarcinoma	Johnston, Sterling	The University of Texas at Austin	\$1,443,367
31	RP210105	HIHRRRA	2.8	Targeting Lymphotoxin Beta Receptor in Sensory Neurons for Control of Chemotherapy-Induced Neuropathic Pain	Tumanov, Alexei	The University of Texas Health Science Center at San Antonio	\$249,996
32	RP210068	HIHRRRA	2.8	Role of Aberrant Translational Quality Control in Tumorigenesis of Glioblastoma	Wu, Zhihao	Southern Methodist University	\$249,272
33	RP210102	HIHRRRA	2.8	Deciphering BRCA1-BARD1 E3 Ligase Activity in Genome Maintenance and Tumor Suppression	Zhao, Weixing	The University of Texas Health Science Center at San Antonio	\$250,000
34	RP210099	CFSA	2.8	North Texas Multimodal Small-Animal Imaging Core Facility	Henning, Anke	The University of Texas Southwestern Medical Center	\$3,999,929
35	RP210137	HIHRRRA	2.8	Development of TCR-Based Immunotherapies Targeting Hotspot EGFR Mutations for the Treatment of Non-Small Cell Lung Cancer	Reuben, Alexandre	The University of Texas M. D. Anderson Cancer Center	\$250,000
36	RP210209	CFSA	2.9	North Texas Clinical Pharmacology Cancer Core	Putnam, William	Texas Tech University Health Sciences Center	\$2,965,226
37	RP210092	HIHRRRA	3.0	Antibody-Drug Conjugate Combination Treatment for Targeting Colorectal Cancer Cell Plasticity	Carmon, Kendra	The University of Texas Health Science Center at Houston	\$250,000
38	RP210131	HIHRRRA	3.0	Antibody like Therapeutics That Target Polyclonal T Cells to CMV-Positive Glioblastomas	Maynard, Jennifer	The University of Texas at Austin	\$250,000
39	RP210075	HIHRRRA	3.0	Exploring the Biological Basis of Ethnic and Social Disparities in Pediatric Acute Lymphoblastic Leukemia Outcomes	Schraw, Jeremy	Baylor College of Medicine	\$249,999
40	RP210199	HIHRRRA	3.0	Treating Metastatic Cancer Using Microbubble-Assisted Ultrasound-Guided Immunotherapy of Cancer of Cancer (MUSIC)	Lux, Jacques	The University of Texas Southwestern Medical Center	\$249,011

41	RP210127	HIHRRA	3.0	Engineered Enteric Nerve-Perineural Invasion Models to Improve Predictive Preclinical Screens in Early-Stage Colorectal Adenocarcinoma	Raghavan, Shreya	Texas A&M University	\$250,000
42	RP210148	HIHRRA	3.0	Novel Pharmacodynamic Assay to Predict Response to CDK4/6 Inhibitor Therapy	Trivedi, Meghana	University of Houston	\$250,000
43	RP210119	CFSA	3.1	A Preclinical Development Core for Large-Molecule Therapeutics	Liu, Qingyun	The University of Texas Health Science Center at Houston	\$3,999,999
44	RP210064	CFSA	3.1	The Adolescent and Childhood Cancer Epidemiology and Susceptibility Service (ACCESS) for Texas	Scheurer, Michael	Baylor College of Medicine	*\$4,000,000
45	RP210130	CFSA	3.1	Data Management and Analysis Core for Comparative Effectiveness Research on Cancer in Texas	Kuo, Yong-Fang	The University of Texas Medical Branch at Galveston	\$2,936,731
46	RP210070	HIHRRA	3.1	Tunable Epigenetic Remodeling to Modulate CAR T-Cell-Based Immunotherapy	Zhou, Yubin	Texas A&M University System Health Science Center	\$250,000
47	RP210132	HIHRRA	3.1	Synergy Between Epigenetic Reprogramming and Wnt Inhibition to Enhance Neuroendocrine Tumor Radionuclide Therapy	Frost, Jeffrey	The University of Texas Health Science Center at Houston	\$249,999
48	RP210153	TREC	3.1	UTEP/UTMDACC Partnership for Hispanic Cancer Disparities Research	Cox, Marc	The University of Texas at El Paso	\$5,881,734
49	RP210183	HIHRRA	3.3	Virulence Modulation of Helicobacter pylori, the Strongest Risk Factor for Gastric Cancer	Kearney, Christopher	Baylor University	\$248,938
50	RP210213	HIHRRA	3.3	Therapeutic Inhibition of Cholangiocarcinoma Progression by Targeting Tumor-Lymphatic Cross Talk	Chakraborty, Sanjukta	Texas A&M University System Health Science Center	\$250,000

*Note the SRC recommended reduced budgets for applications # RP210180 and #RP210064, the reductions are reflected in the table.

CFSA = Core Facility Support Awards

CTNA = Clinical Trials Network Award

ECI = Early Clinical Investigator Awards

HIHR = High-Impact/High Risk Awards

TCTPA = Texas Clinical Trials Participation Award

TREC = Texas Regional Excellence in Cancer Award

FY 2021 Cycles 10, 11 and 12 Proposed Recruitment Awards

Rank	ID	Grant	Candidate	Organization	Budget	Score
1	RR210082	RFTFM	Dr. Kyle Eagen	Baylor College of Medicine	\$2,000,000	1.0
2	RR210066	RFTFM	Dr. Chad W. Johnston	Baylor College of Medicine	\$2,000,000	1.0
3	RR210056	RFTFM	Dr. Xia Gao	Baylor College of Medicine	\$2,000,000	1.0
4	RR210059	RFTFM	Dr. Javier Garcia-Bermudez	The University of Texas Southwestern Medical Center	\$2,000,000	1.0
5	RR210067	RRS	Dr. Yong Lu	The Methodist Hospital Research Institute	\$3,998,389	1.7
6	RR210085	RFTFM	Dr. Yuan Pan	The University of Texas M. D. Anderson Cancer Center	\$2,000,000	1.9
7	RR210077	RFTFM	Dr. Edward J. Grow	The University of Texas Southwestern Medical Center	\$2,000,000	1.9
8	RR210083	RFTFM	Dr. David Braun	The University of Texas M. D. Anderson Cancer Center	\$2,000,000	2.0
9	RR210086	RFTFM	Dr. Seungwon "Sebastian" Choi	The University of Texas Southwestern Medical Center	\$2,000,000	2.0
10	RR210079	RRS	Dr. Tian Zhang	The University of Texas Southwestern Medical Center	\$4,000,000	2.0
11	RR210080	RFTFM	Dr. Jason George	Texas A&M Engineering Experiment Station	\$1,999,309	2.0
12	RR210070	RFTFM	Dr. Shih-Han Lee	The University of Texas M. D. Anderson Cancer Center	\$2,000,000	2.3

RRS = Recruitment of Rising Stars

RFTFM = Recruitment of First-Time, Tenure Track Faculty Members

Dr. Willson also presented the proposed FY 2022 and FY 2023 Requests for Applications:

Proposed FY 2022 and FY 2023 Requests for Applications

Grant Mechanism	Applications Due	Review Panel	Awards Announced	Budget Year
Core Facility Support Awards	Jan 2022	May 2022	August 2022	FY 2022
High-Impact/High Risk	Jan 2022	May 2022	August 2022	FY 2022
Early Clinical Investigator	Jan 2022	May 2022	August 2022	FY 2022
Clinical Trials Network	Jan 2022	May 2022	August 2022	FY 2022
Texas Regional Excellence in Cancer	Sept 2022	Nov 2022	Jan 2023	FY 2023

Conflict of Interest Notification

Presiding Officer Margo noted for the record that Dr. Rosenfeld reported a conflict of interest with two academic research awards, RP210140 and RP210208.

Approval Process – Academic Research Awards

Presiding Officer Margo called for a vote on the award recommendations, with the first vote addressing RP210140 and RP210208.

MOTION:

On a motion made by Dr. Rice and seconded by Mr. Montgomery the Oversight Committee members voted to approve the PIC’s recommendations for RP210140 and RP210208. No members voted to disapprove the recommendations.

Presiding Officer Margo noted for the record that Dr. Rosenfeld did not vote. Presiding Officer Margo then called for a vote on the remaining eight slates of academic research award recommendations.

MOTION:

On a motion made by Dr. Rice and seconded by Mr. Montgomery the Oversight Committee members voted unanimously to approve the PIC’s recommendations for the remaining proposed academic research grant awards.

MOTION:

On a motion made by Dr. Rice and seconded by Mr. Montgomery, the Oversight Committee members voted to approve the delegation of contract negotiation authority to CPRIT’s CEO and staff and authorized the CEO to sign the contracts on behalf of CPRIT.

Following the vote on the award recommendations, Presiding Officer Margo requested a motion regarding the proposed FY 2022 and FY 2023 RFAs presented by Dr. Willson.

MOTION:

On a motion made by Mr. Montgomery and seconded by Dr. Rice, the Oversight Committee members unanimously voted to approve the proposed FY 2022 and FY 2023 RFAs as presented by Dr. Willson.

Chief Prevention Officer Report – Agenda Item 8, Tab 5

Presiding Officer Margo recognized Chief Prevention Officer Ramona Magid to update the Oversight Committee on the prevention program and to present the prevention awards. Ms. Magid presented her update and introduced the nine prevention program projects in the second cycle of FY 2021, totaling \$11,396,581, recommended by the Prevention Review Council and PIC. She explained that applicants submitted the recommended applications in response to four grant mechanisms: *Evidence-Based Cancer Prevention Services, Expansion of Cancer Prevention Services to Rural and Medically Underserved Populations, Tobacco Control and Lung Cancer Screening, and Dissemination of CPRIT-Funded Cancer Control Interventions*. Ms. Magid reported that all applications address at least two of the Prevention Program priorities.

An Oversight Committee member asked if CPRIT allowed COVID-19 vaccinations as part of the clinical service delivery of prevention projects. Ms. Magid replied that grantees do not provide these vaccinations, but several grantees provide education about and navigation services to COVID-19 vaccination.

Proposed FY 2021 Cycle 2 Prevention Program Awards

ID	Grant	Application Title	PD	Organization	Score	Rank	Budget
PP210045	DI	Dissemination of a Mailed Stool Testing Program for Colorectal Cancer Prevention in Underserved Communities in Texas	Pignone, Michael	The University of Texas at Austin	1.00	1	\$300,000
PP210049	EBP	Texas Southern University Breast Cancer Screening and Prevention Center	Ajewole, Veronica	Texas Southern University	1.80	2	\$1,000,000
PP210020	EPS	Vaccinating Medically Underserved Women Against HPV: Expansion of Clinical Services to Increase Access	Berenson, Abbey	The University of Texas Medical Branch at Galveston	2.00	3	\$1,999,988
PP210042	TCL	A Regional Expansion of Lung Cancer Screening and Patient Navigation (E-LSPAN)	Argenbright, Keith	The University of Texas Southwestern Medical Center	2.10	4	\$1,999,993
PP210026	DI	Taking Texas Tobacco Free: Dissemination to and Implementation Within Agencies Serving Texans Experiencing Homelessness	Reitzel, Lorraine	University of Houston	2.70	5	\$299,978
PP210027	TCL	Increasing Accessibility to Smoking Cessation and Lung Cancer Screening Services for Low-Income/Uninsured Texans	McKnight, Jason	Texas A&M University System Health Science Center	3.10	6	\$999,947
PP210031	DI	Application of mHealth Technologies to Improve Latino Childhood Cancer Survivor Engagement and Use of Evidence for Personalized Follow-Up Care and Screening	Poplack, David	Baylor College of Medicine	3.30	7	\$299,982
PP210007	EPS	Strengthening Safety Net Health Systems to Improve Cervical and Colorectal Cancer Screening and Follow-up among the Medically Underserved	Montealegre, Jane R	Baylor College of Medicine	3.30	8	\$2,497,029
PP210044	TCL	Expansion of the Lung Cancer Screening and Tobacco Control (LCTC) Network to Rural and Medically Underserved Populations	Zoorob, Roger	Baylor College of Medicine	3.60	9	\$1,999,664

DI: Dissemination of CPRIT-Funded Cancer Control Interventions

EBP: Evidence-Based Cancer Prevention Services

EPS: Expansion of Cancer Prevention Services to Rural and Medically Underserved Populations

TCL: Tobacco Control and Lung Cancer Screening

Compliance Certification

Presiding Officer Margo reminded members that Mr. Burgess previously certified compliance of the prevention awards process.

Conflict of Interest Notification

Presiding Officer Margo noted for the record that no Oversight Committee member reported a conflict of interest with any of the proposed prevention awards.

Approval Process -Prevention Grant Award

Presiding Officer Margo called for a vote on the nine proposed award recommendations.

MOTION:

On a motion made by Mr. Montgomery and seconded by Dr. Rice, the Oversight Committee unanimously voted to approve the PIC’s recommendations for the nine prevention grants recommended by the PIC.

MOTION:

On a motion made by Mr. Montgomery and seconded by Dr. Rice, the Oversight Committee unanimously voted to approve the delegation of contract negotiation authority to the CEO and CPRIT staff and to authorize the CEO to sign the contracts on behalf of CPRIT.

Chief Product Development Officer Report – Agenda Item 9, Tab 6

Presiding Officer Margo recognized Chief Product Development Officer Dr. Cindy WalkerPeach to present the proposed product development research award recommendations and to provide the product development research program update.

Dr. WalkerPeach presented the PIC’s two product development research award recommendations, totaling \$27,565,207 for the FY 2021 review cycle: Dialectic Therapeutics, Inc. and Marker Therapeutics, Inc.

FY 2021 Proposed Product Development Research Awards

Rank	ID	Grant	Company	Project	Score	Budget
1	DP210005	Texas Company	Dialectic Therapeutics	Clinical Development of DT2216, a First-in-Class APTaD™ for Cancer Therapy	3.0	\$14,449,638
2	DP210042	Texas Company	Marker Therapeutics	Efficacy of a Multi Tumor Associated Antigen Specific T Cell Therapy in AML Patients following Allogeneic Stem Cell Transplant	2.2	\$13,115,569
					Total	\$27,565,207

Dr. WalkerPeach also provided an update regarding the status of the applications under review in the first review cycle for FY 2022 and presented staff’s proposal to revise CPRIT’s matching funds policy for repeat product development grantees. She finished her report with the presentation of the planned review timeline and three product development research RFAs for the second review cycle in FY 2022.

Compliance Certification

Presiding Officer Margo reminded members that Mr. Burgess previously certified compliance of the product development awards process.

Conflict of Interest Notification

Presiding Officer Margo noted for the record that no Oversight Committee member reported a conflict of interest with any of the proposed product development awards.

Approval Process – Product Development Research Awards

Presiding Officer Margo called for a vote on the two proposed award recommendations.

MOTION:

On a motion made by Mr. Montgomery and seconded by Dr. Hernandez, the Oversight Committee unanimously voted to approve the PIC's recommendations for product development research awards to Dialectic Therapeutics and Marker Therapeutics as presented by Dr. WalkerPeach.

MOTION:

On a motion made by Mr. Montgomery and seconded by Dr. Rice, the Oversight Committee unanimously voted to approve the delegation of contract negotiation authority to the CEO and CPRIT staff and to authorize the CEO to sign the contracts on behalf of CPRIT.

MOTION:

On a motion made by Mr. Montgomery and seconded by Dr. Rice, the Oversight Committee unanimously voted to authorize CPRIT to disburse grant funds via advance payments to Dialectic Therapeutics and Marker Therapeutics upon execution of the award contracts and the successful completion of tranches.

Following the vote on the award recommendations, Presiding Officer Margo requested a motion regarding the proposed policy change for matching funds required for multiple product development grants, as presented by Dr. WalkerPeach.

MOTION:

On a motion made by Mr. Rosenfeld and seconded by Mr. Montgomery, the Oversight Committee unanimously voted to approve the change to CPRIT's matching funds policy for companies that have received multiple product development awards as outlined by CPRIT's Chief Product Development Officer.

Presiding Officer Margo noted for the record that the Oversight Committee would leave Agenda Item 9 pending and take up the remaining point in closed session later in the meeting.

Internal Auditor Report – Agenda Item 10, Tab 7

Presiding Officer Margo recognized CPRIT internal auditor Dan Graves with Weaver and Tidwell. Mr. Graves provided an update on current internal audit activities and the FY 2022 Internal Audit Plan. He explained that the State Auditor’s Office (SAO) has a requirement for the submission of an annual internal audit report and that a component of the report is the inclusion of the proposed FY 2022 Internal Audit Plan. The report is due November 1, 2021.

MOTION:

On a motion by Dr. Patel and seconded by Mr. Montgomery, the Oversight Committee unanimously voted to approve the FY 2022 Internal Audit Plan.

Scientific Research and Prevention Program Committee Appointments – Agenda Item 11, Tab 8

The Chair recognized Mr. Roberts to present the Scientific Research and Prevention Program Committee Appointments. Mr. Roberts presented his four appointments to the scientific research and prevention program committee, which he summarized on page 8-2 of the meeting book. The Nominations Subcommittee reviewed and recommended the appointments at their August 13, 2021, meeting.

MOTION:

On a motion by Mr. Montgomery and seconded by Dr. Patel, the Oversight Committee unanimously voted to approve the four appointments to the scientific research and prevention program committee.

Advisory Committees – Item 12, Tab 9

The Chair recognized Dr. Willson to present Dr. Osborne, Chair of the Clinical Trials Advisory Committee to present the Clinical Trial Advisory Committee’s Annual Report.

Clinical Trial Advisory Committee Annual Report Presentation

Dr. Osborne presented the Clinical Trials Advisory Committee’s report and recommendations.

In response to an Oversight Committee member’s question regarding the number of patients historically enrolled in clinical trials, Dr. Osborne explained that few patients enroll in trials – approximately only 4% of eligible candidates.

Responding to an Oversight Committee member’s question about how CPRIT and an institution may ensure that the early clinical investigator required 50% “protected time” for Early Clinical Investigator’s awardees, Dr. Osborne noted that the institution keeps time sheets.

The Oversight Committee members thanked Dr. Osborne for the annual report presentation and his leadership as Chair of the Clinical Trials Advisory Committee. Mr. Roberts thanked Dr. Osborne for also serving on the CPRITs Chief Scientific Officer interview committee.

Appointment of Advisory Committee Members

Presiding Officer Margo recognized Mr. Roberts to present the Presiding Officer's new appointments to CPRIT's advisory committees and the proposed schedule for FY 2022 advisory committee reports.

Mr. Roberts presented the four advisory committee appointments: Lisa Tichenor (Advisory Committee on Childhood Cancer), Smita Bhaskara, M.D. (Advisory Committee on Childhood Cancer), Phillip Neff, M.D. (Advisory Committee on Childhood Cancer) and Jon Mogford, Ph.D. (Product Development Advisory Committee). Mr. Roberts also discussed the proposed schedule for FY 2022 advisory committee annual reports.

MOTION:

On a motion made by Dr. Patel and seconded by Dr. Rice the Oversight Committee members voted unanimously to approve the four new appointments to the advisory committees.

FY 2022 Honoraria Policy – Agenda Item 13, Tab 10

Presiding Officer Margo recognized Mr. Roberts to present the FY 2022 honoraria policy. Mr. Roberts reported that there are no changes to the FY 2022 honoraria policy from the FY 2021 policy approved by the Oversight Committee last year.

MOTION:

On a motion made by Mr. Montgomery and seconded by Dr. Patel the Oversight Committee members voted unanimously to approve the FY 2022 honoraria policy.

Health & Safety Code § 102.1062 Waivers – Agenda Item 14, Tab 11

Presiding Officer Margo recognized Mr. Roberts to present the Health and Safety Code Section 102.1062 waivers for FY 2022. Mr. Roberts presented the four waivers for FY 2022.

MOTION:

On a motion made by Dr. Rice and seconded by Mr. Montgomery the Oversight Committee members voted unanimously to approve the Health and Safety Code Section 102.1062 waivers for FY 2022.

Amendments to 25 T.A.C. Chapters 703 – Item 15, Tab 12

Presiding Officer Margo recognized CPRIT assistant general counsel Cameron Eckel to discuss the proposed administrative rule change. Ms. Eckel reviewed the final order approving the amendment to Chapter 703. CPRIT will file the final order with the Secretary of State for final adoption.

MOTION:

On a motion made by Dr. Rice and seconded by Mr. Montgomery, the Oversight Committee unanimously voted to approve the final order adopting rule change to the Texas Administrative Code Chapter 703.

Chief Operating Officer Report – Agenda Item 16, Tab 13

Presiding Officer Margo recognized Ms. McConnell to provide the Chief Operating Officer Report. Ms. McConnell updated the Oversight Committee regarding third quarter financial information, performance measures, debt issuance, service contract renewals, and the imminent issuance of the State Auditor's Office audit over CPRIT's grant management processes.

Ms. McConnell reported on the de-obligation of approximately \$85 million from the unspent funds of closed grant awards. She explained that FY 2021 is the first year that the agency is using de-obligated funds to support the grant awards that the Oversight Committee has approved, with CPRIT applying \$60 million to the grant awards in FY 2021. CPRIT may apply the remaining amount to grant awards approved in future funding years. Ms. McConnell explained other circumstances may reduce that de-obligated fund amount such as the unbudgeted draws by the Employees Retirement System (ERS) to pay post-retirement benefits of former Texas Cancer Registry employees at the Department of State Health Services or former CPRIT employees. The amount drawn annually has grown over the past 12 years from \$10,000 to \$380,000. There is no standard pattern to the amount drawn by ERS.

Oversight Committee members discussed the de-obligated grant funds with Ms. McConnell.

Contract Approvals – Agenda Item 17, Tab 14

Presiding Officer Margo recognized Ms. McConnell to present proposed contract approvals. Ms. McConnell summarized the four contract renewals exceeding \$100,000 that require Oversight Committee approval: Icon, Hahn Public, Perryman Group, and Weaver. She noted that Oversight Committee approval is not necessary for outside counsel services because CPRIT will contract with two separate law firms and each contract will be less than \$100,000. Ms. McConnell reminded members that she will send out financial disclosure forms.

MOTION:

On a motion made by Dr. Rice and seconded by Dr. Patel, the Oversight Committee unanimously voted to approve contracts with The Perryman Group, Weaver and Tidwell, Hahn Public, and ICON Clinical Research.

Subcommittee Business – Agenda Item 18, Tab 15

Presiding Officer Margo informed the committee members that CPRIT included the proposed subcommittee assignments, including subcommittee chair positions, for FY 2022 - 2023.

In addition, Presiding Officer Margo explained that the Oversight Committee will move the responsibilities originally assigned to the Nominations subcommittee to the Board Governance subcommittee in FY 2022. CPRIT included a revised Board Governance subcommittee charter that reflects the new duties in the meeting packet.

MOTION:

On a motion made by Dr. Rosenfeld and seconded by Mr. Montgomery, the Oversight Committee unanimously voted to approve the new subcommittee assignments for FY 2022 and 2023.

MOTION:

On a motion made by Dr. Rosenfeld and seconded by Dr. Patel, the Oversight Committee unanimously voted to approve the proposed changes to the Board Governance charter.

Election of Board Officers – Agenda Item 20, Tab 16

Presiding Officer Margo informed the committee members that the Nominations Subcommittee met August 13 and unanimously recommended a slate of officers to serve two-year terms ending in August 2023. The proposed slate is Dr. Mahendra Patel as presiding officer, Dr. David Cummings as vice presiding officer, and Cindy Payne as board secretary.

MOTION:

On a motion made by Mr. Margo and seconded by Dr. Rosenfeld, the Oversight Committee unanimously voted to approve Dr. Mahendra Patel as Presiding Officer, Dr. David Cummings as Vice Presiding Officer, and Cindy Payne as Board Secretary to serve the Oversight Committee for FY 2022 and 2023.

Wayne Roberts and CPRIT staff thanked Mr. Margo for his service as the Presiding Officer.

Future Meeting Dates and Agenda Items – Agenda Item 23, Tab 17

Taking agenda item 23 out of order, Presiding Officer Margo presented the proposed dates for the Oversight Committee’s regular quarterly meetings and subcommittee meetings for FY 2022.

MOTION:

On a motion made by Dr. Rice and seconded by Mr. Montgomery, the Oversight Committee unanimously voted to approve the proposed meeting dates for the regular meetings of the Oversight Committee and the subcommittees for FY 2022.

Tribute to Jim Willson

Presiding Officer Margo announced that this is Dr. Jim Willson’s last meeting as Chief Scientific Officer. Presiding Officer Margo thanked Dr. Willson for serving as a remarkable advocate for the academic research program and for CPRIT’s mission and spoke for the board and for CPRIT staff in appreciation of Dr. Willson’s tremendous work on behalf of Texans. CPRIT played a short video of several CPRIT grantees and colleagues conveying gratitude for his five years at CPRIT.

Mr. Roberts presented Dr. Willson with a Governor’s proclamation. Presiding Officer Margo recognized committee members for remarks. Oversight Committee members made remarks. Presiding Officer Margo read the honorary resolution.

WHEREAS, James K.V. Willson, M.D. has served as the Chief Scientific Officer of the Cancer Prevention and Research Institute of Texas since March 1, 2016; and

WHEREAS, Dr. Willson worked selflessly for and on behalf of CPRIT, giving his time, reputation, wisdom, expertise, and energy to extend lives and improve the health of Texans; and

WHEREAS, Dr. Willson earned the respect and admiration of the Oversight Committee, his CPRIT colleagues, and the greater cancer research community through his leadership of CPRIT's academic research program; and

WHEREAS, Dr. Willson was instrumental in the passage of Proposition 6 in November 2019, ensuring an additional \$3 billion to accelerate the momentum in the state's historic fight against cancer through the next decade;

WHEREAS, Dr. Willson provided steadfast guidance to the cancer research community and CPRIT during the unprecedented challenges presented by the global COVID-19 pandemic;

WHEREAS, Dr. Willson faithfully performed the duties of his position with equanimity, persistence, and poise; and

WHEREAS, CPRIT's mission of promoting academic research, prevention, and product development research progressed under Dr. Willson's guidance and leadership to the benefit of all Texans; now, therefore, be it

RESOLVED, THAT the Oversight Committee of CPRIT hereby recognizes James K.V. Willson, M.D. for his distinguished service to the citizens of the State of Texas, and expresses its gratitude for his many and lasting contributions to CPRIT; and, be it further

RESOLVED, THAT an official copy of this resolution be prepared for Dr. Willson as an expression of high regard by Oversight Committee members and CPRIT staff.

MOTION:

On a motion made by Dr. Rosenfeld and seconded by Dr. Rice, the Oversight Committee unanimously voted to approve the honorary resolution.

**Personnel – Chief Scientific Officer – Agenda Item 19
Chief Product Development Officer Report (pending discussion item) – Agenda Item 9**

Turning the Agenda Item 19, Presiding Officer Margo informed the Oversight Committee that they will convene in closed session for discussion regarding the Chief Scientific Officer position pursuant to Texas Open Meetings Act Section 551.074. He explained that the Oversight Committee will also take up in closed session the pending discussion under Agenda Item 9 related to managing, acquiring, or selling securities or other revenue sharing obligations pursuant to Texas Health & Safety Code Section 102.107(b). He asked Mr. Roberts, Ms. Lisa Nelson, Ms. Doyle, Dr. WalkerPeach, and Ms. Tracey Davies to join the Oversight Committee in closed session

The Oversight Committee convened in closed session via a secure video channel at 11:26 a.m. Presiding Officer Margo reconvened the open meeting at 12:13 p.m.

MOTION:

On a motion made by Mr. Montgomery and seconded by Dr. Rice, the Oversight Committee unanimously voted to set the exempt salary for the Chief Scientific Officer position to the legislatively authorized \$608,850 effective on or after September 1, 2021.

Adjournment – Agenda Item 24

MOTION:

There being no further business, the Oversight Committee unanimously voted to approve a motion to adjourn made by Presiding Officer Margo and seconded by Dr. Rice.

Meeting adjourned at 12:14 a.m.

Cynthia Barberio Payne
Signature

Nov. 18, 2021
Date



A handwritten signature in blue ink, appearing to read "Jim Magid".

8/18/21

CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

August 5, 2021

Dear Oversight Committee Members:

I am pleased to present the Program Integration Committee's (PIC) unanimous recommendations for funding 73 grant applications totaling \$142,377,830. The PIC recommendations for 62 academic research, 9 prevention, and 2 product development research grant awards are attached.

Dr. Jim Willson, CPRIT's Chief Scientific Officer, Ramona Magid, CPRIT's Chief Prevention Officer, and Dr. Cindy WalkerPeach, CPRIT's Chief Product Development Officer, have prepared overviews of the academic research, prevention, and product development research slates to assist your evaluation of the recommended awards. The overviews are intended to provide a comprehensive summary with enough detail to understand the substance of the proposal and the reasons endorsing grant funding. In addition to the full overviews, all the information considered by each Review Council is available by clicking on the appropriate link in the portal. This information includes the application, peer reviewer critiques, and the CEO affidavit for each proposal.

The approval of these grant recommendations is governed by a statutory process that requires two-thirds of the members present and voting to approve each recommendation. Vince Burgess, CPRIT's Chief Compliance Officer, will certify that the review process for the recommended grants followed CPRIT's award process prior to any Oversight Committee action.

The award recommendations will not be considered final until the Oversight Committee meeting on August 18, 2021. Consistent with the non-disclosure agreement that all Oversight Committee members have signed, the recommendations should be kept confidential and not be disclosed to anyone until the award list is publicly announced at the Oversight Committee meeting. I request that Oversight Committee members not print, email or save to your computer's hard drive any material on the portal. I appreciate your assistance in taking all necessary precautions to protect this information.

If you have any questions or would like more information on the review process or any of the projects recommended for an award, CPRIT's staff, including myself and Dr. Willson, Dr. WalkerPeach, and Ms. Magid are always available. Please feel free to contact us directly should you have any questions. The programs that will be supported by the CPRIT awards are an important step in our efforts to mitigate the effects of cancer in Texas.

Thank you for being part of this endeavor.

Sincerely,
Wayne R. Roberts,
Chief Executive Officer

Academic Research Grant Award Recommendations

Rank	Application ID	Mechanism	PI	Application Title	Organization	Budget	Final Overall Score
1	RP210227	CFSA	Edwards, Dean	Proteomics and Metabolomics Core Facility	Baylor College of Medicine	\$3,977,681	1.0
2	RP210176	ECI	Draetta, Gulio	CPRIT Early Clinical Investigator Award: Moran Amit	The University of Texas M. D. Anderson Cancer Center	\$1,499,042	1.0
3	RP210208	CFSA	McHardy, Stanton	Center for Innovative Drug Discovery: Expansion of a Highly Productive Shared Cancer Drug Discovery Resource for Texas	The University of Texas at San Antonio	\$3,087,131	1.1
4	RP210143	TCTPA	Mims, Martha	Dan L. Duncan Comprehensive Cancer Center (DLDCCC) Harris Health Clinical Trials Financial Support Project	Baylor College of Medicine	\$1,500,000	1.5
5	RP210165	HIHRRRA	Li, Xiujun (James)	Rapid Point-of-Care Detection of Ovarian Cancer Biomarkers Using a Common Thermometer for Low-Resource Settings	The University of Texas at El Paso	\$249,999	1.6
6	RP210115	TCTPA	Gerber, David	Enhancing Access to and Diversity in Cancer Clinical Trials Through a Financial Reimbursement and Outreach Program	The University of Texas Southwestern Medical Center	\$1,499,327	1.7
7	RP210159	ECI	Draetta, Gulio	CPRIT Early Clinical Investigator Award: Carl Gay	The University of Texas M. D. Anderson Cancer Center	\$1,499,997	1.8

PIC Recommendation
FY2021 (August)

Rank	Application ID	Mechanism	PI	Application Title	Organization	Budget	Final Overall Score
8	RP210088	CFSA	Dalby, Kevin	Targeted Therapeutic Drug Discovery and Development Program	The University of Texas at Austin	\$3,989,441	1.9
9	RP210205	HIHRRRA	Veisoh, Omid	Cytokine Factories for the Treatment of Mesothelioma	Rice University	\$250,000	1.9
10	RP210173	HIHRRRA	Hart, Traver	Multiplex CRISPR Genetic Modeling of Polypharmacology for Precision Medicine	The University of Texas M. D. Anderson Cancer Center	\$250,000	1.9
11	RP210108	CFSA	Stephan, Clifford	The GCC Microphysiological Lead Optimization and Toxicity Screening Facility	Texas A&M University System Health Science Center	\$3,973,083	2.0
12	RP210144	HIHRRRA	Rostomily, Robert	Leveraging Glioma Stem Cell Electrophysiology for Therapy	The Methodist Hospital Research Institute	\$248,028	2.0
13	RP210168	HIHRRRA	Yi, Qing	Overcoming Myeloma Resistance to Proteasome Inhibitors	The Methodist Hospital Research Institute	\$250,000	2.0
14	RP210062	HIHRRRA	Zhou, Jia	Protein Degradation of CDK9 for Treatment of Drug-Resistant Mantle Cell Lymphoma	The University of Texas Medical Branch at Galveston	\$250,000	2.0
15	RP210154	TREC	Reynolds, Charles	Texas Regional Excellence in Cancer Developmental Therapeutics Center at TTUHSC	Texas Tech University Health Sciences Center	\$5,999,936	2.0

PIC Recommendation
FY2021 (August)

Rank	Application ID	Mechanism	PI	Application Title	Organization	Budget	Final Overall Score
16	RP210073	HIHRRA	DePinho, Ronald	Identification of Collateral Lethal and Synthetic Lethal Targets in Pancreatic and Colorectal Cancers	The University of Texas M. D. Anderson Cancer Center	\$249,994	2.1
17	RP210111	HIHRRA	Pan, Sheng	Single-Cell Proteomics to Dissect Intratumor Heterogeneity	The University of Texas Health Science Center at Houston	\$250,000	2.1
18	RP210134	HIHRRA	Tambar, Uttam	High-Throughput Discovery of Anticancer Protein Degradors	The University of Texas Southwestern Medical Center	\$250,000	2.2
19	RP210116	CFSA	Bao, Gang	The Genetic Design and Engineering Center (GDEC): A CPRIT Core Facility	Rice University	\$4,000,000	2.3
20	RP210158	HIHRRA	Mamonkin, Maksim	Improving CAR TCell Therapy of TALL by Cotargeting Additional Antigens	Baylor College of Medicine	\$250,000	2.3
21	RP210206	HIHRRA	Nguyen, Kytai	Novel Tumor-Specific Bioactive Nanoparticles for Cancer Therapy	The University of Texas at Arlington	\$249,999	2.4
22	RP210180	CFSA	CHAUHAN, SUBHASH	Integrated Cancer Research Core (ICRC)	The University of Texas Rio Grande Valley	\$2,525,000	2.5
23	RP210126	CFSA	Berton, Michael	High-Parameter Analysis, Sorting, and Imaging Flow Cytometry Shared Resource	The University of Texas Health Science Center at San Antonio	\$3,645,500	2.5
24	RP210122	CTNA	Overman, Michael	Building a Clinical Trial Network for Texas Community Affiliates	The University of Texas M. D. Anderson Cancer Center	\$3,000,000	2.5

PIC Recommendation
FY2021 (August)

Rank	Application ID	Mechanism	PI	Application Title	Organization	Budget	Final Overall Score
25	RP210164	ECI	Hromas, Robert	Early Clinical Investigator Award: William Kelly	The University of Texas Health Science Center at San Antonio	\$1,499,985	2.5
26	RP210140	ECI	Arteaga, Carlos	Targeting Altered Metabolism in IDH Mutant Glioma	The University of Texas Southwestern Medical Center	\$1,500,000	2.6
27	RP210089	HIHRRRA	Kim, Hyun Jung	Dissecting Therapeutic Immunomodulation of Gut Microbiome on Colorectal Cancer	The University of Texas at Austin	\$250,000	2.6
28	RP210079	HIHRRRA	Cambronne, Xiaolu	Targeting Mitochondrial NAD ⁺ in Leukemias	The University of Texas at Austin	\$250,000	2.7
29	RP210236	HIHRRRA	Qin, Zhenpeng	Magnetomechanical Modulation of Blood-Brain Barrier Permeability	The University of Texas at Dallas	\$250,000	2.7
30	RP210234	ECI	Johnston, Sterling	Targeting Src Homology-2 Domain-Containing Phosphatase to Overcome Resistance to Immune Checkpoint Blockade in Pancreatic Ductal Adenocarcinoma	The University of Texas at Austin	\$1,443,367	2.7
31	RP210105	HIHRRRA	Tumanov, Alexei	Targeting Lymphotoxin Beta Receptor in Sensory Neurons for Control of Chemotherapy-Induced Neuropathic Pain	The University of Texas Health Science Center at San Antonio	\$249,996	2.8

PIC Recommendation
 FY2021 (August)

Rank	Application ID	Mechanism	PI	Application Title	Organization	Budget	Final Overall Score
32	RP210068	HIHRRRA	Wu, Zhihao	Role of Aberrant Translational Quality Control in Tumorigenesis of Glioblastoma	Southern Methodist University	\$249,272	2.8
33	RP210102	HIHRRRA	ZHAO, WEIXING	Deciphering BRCA1-BARD1 E3 Ligase Activity in Genome Maintenance and Tumor Suppression	The University of Texas Health Science Center at San Antonio	\$250,000	2.8
34	RP210099	CFSA	Henning, Anke	North Texas Multimodal Small-Animal Imaging Core Facility	The University of Texas Southwestern Medical Center	\$3,999,929	2.8
35	RP210137	HIHRRRA	Reuben, Alexandre	Development of TCR-Based Immunotherapies Targeting Hotspot EGFR Mutations for the Treatment of Non-Small Cell Lung Cancer	The University of Texas M. D. Anderson Cancer Center	\$250,000	2.8
36	RP210209	CFSA	Putnam, William	North Texas Clinical Pharmacology Cancer Core	Texas Tech University Health Sciences Center	\$2,965,226	2.9
37	RP210092	HIHRRRA	Carmon, Kendra	Antibody-Drug Conjugate Combination Treatment for Targeting Colorectal Cancer Cell Plasticity	The University of Texas Health Science Center at Houston	\$250,000	3.0
38	RP210131	HIHRRRA	Maynard, Jennifer	Antibodylike Therapeutics That Target Polyclonal T Cells to CMVPositive Glioblastomas	The University of Texas at Austin	\$250,000	3.0

PIC Recommendation
FY2021 (August)

Rank	Application ID	Mechanism	PI	Application Title	Organization	Budget	Final Overall Score
39	RP210075	HIHRRRA	Schraw, Jeremy	Exploring the Biological Basis of Ethnic and Social Disparities in Pediatric Acute Lymphoblastic Leukemia Outcomes	Baylor College of Medicine	\$249,999	3.0
40	RP210199	HIHRRRA	Lux, Jacques	Treating Metastatic Cancer Using Microbubble-Assisted Ultrasound-Guided Immunotherapy of Cancer of Cancer (MUSIC)	The University of Texas Southwestern Medical Center	\$249,011	3.0
41	RP210127	HIHRRRA	Raghavan, Shreya	Engineered Enteric Nerve-Perineural Invasion Models to Improve Predictive Preclinical Screens in Early-Stage Colorectal Adenocarcinoma	Texas A&M University	\$250,000	3.0
42	RP210148	HIHRRRA	Trivedi, Meghana	Novel Pharmacodynamic Assay to Predict Response to CDK4/6 Inhibitor Therapy	University of Houston	\$250,000	3.0
43	RP210119	CFSA	Liu, Qingyun	A Preclinical Development Core for Large-Molecule Therapeutics	The University of Texas Health Science Center at Houston	\$3,999,999	3.1
44	RP210064	CFSA	Scheurer, Michael	The Adolescent and Childhood Cancer Epidemiology and Susceptibility Service (ACCESS) for Texas	Baylor College of Medicine	\$4,000,000	3.1

PIC Recommendation
FY2021 (August)

Rank	Application ID	Mechanism	PI	Application Title	Organization	Budget	Final Overall Score
45	RP210130	CFSA	Kuo, Yong-Fang	Data Management and Analysis Core for Comparative Effectiveness Research on Cancer in Texas	The University of Texas Medical Branch at Galveston	\$2,936,731	3.1
46	RP210070	HIHRRRA	Zhou, Yubin	Tunable Epigenetic Remodeling to Modulate CAR TCell-Based Immunotherapy	Texas A&M University System Health Science Center	\$250,000	3.1
47	RP210132	HIHRRRA	Frost, Jeffrey	Synergy Between Epigenetic Reprogramming and Wnt Inhibition to Enhance Neuroendocrine Tumor Radionuclide Therapy	The University of Texas Health Science Center at Houston	\$249,999	3.1
48	RP210153	TREC	Cox, Marc	UTEP/UTMDACC Partnership for Hispanic Cancer Disparities Research	The University of Texas at El Paso	\$5,881,734	3.1
49	RP210183	HIHRRRA	Kearney, Christopher	Virulence Modulation of Helicobacter pylori, the Strongest Risk Factor for Gastric Cancer	Baylor University	\$248,938	3.3
50	RP210213	HIHRRRA	Chakraborty, Sanjukta	Therapeutic Inhibition of Cholangiocarcinoma Progression by Targeting Tumor-Lymphatic Cross Talk	Texas A&M University System Health Science Center	\$250,000	3.3

CFSA: Core Facility Support Awards
CTNA: Clinical Trials Network Award
ECI: Early Clinical Investigator Awards
HIHRRRA: High-Impact/High Risk Awards
TCTPA: Texas Clinical Trials Participation Award
TREC: Texas Regional Excellence in Cancer Award

Academic Research Recruitment Grant Award Recommendations

Rank	Application ID	Mechanism	Candidate	Organization	Budget	Final Overall Score
1	RR210082	RFTFM	Dr. Kyle Eagen	Baylor College of Medicine	\$2,000,000	1.0
2	RR210066	RFTFM	Dr. Chad W. Johnston	Baylor College of Medicine	\$2,000,000	1.0
3	RR210056	RFTFM	Dr. Xia Gao	Baylor College of Medicine	\$2,000,000	1.0
4	RR210059	RFTFM	Dr. Javier Garcia-Bermudez	The University of Texas Southwestern Medical Center	\$2,000,000	1.0
5	RR210067	RRS	Dr. Yong Lu	The Methodist Hospital Research Institute	\$3,998,389	1.7
6	RR210085	RFTFM	Dr. Yuan Pan	The University of Texas M. D. Anderson Cancer Center	\$2,000,000	1.9
7	RR210077	RFTFM	Dr. Edward J. Grow	The University of Texas Southwestern Medical Center	\$2,000,000	1.9
8	RR210083	RFTFM	Dr. David Braun	The University of Texas M. D. Anderson Cancer Center	\$2,000,000	2.0
9	RR210086	RFTFM	Dr. Seungwon "Sebastian" Choi	The University of Texas Southwestern Medical Center	\$2,000,000	2.0
10	RR210079	RRS	Dr. Tian Zhang	The University of Texas Southwestern Medical Center	\$4,000,000	2.0
11	RR210080	RFTFM	Dr. Jason George	Texas A&M Engineering Experiment Station	\$1,999,309	2.0

PIC Recommendation
FY2021 (August)

Rank	Application ID	Mechanism	Candidate	Organization	Budget	Final Overall Score
12	RR210070	RFTFM	Dr. Shih-Han Lee	The University of Texas M. D. Anderson Cancer Center	\$2,000,000	2.3

RFTFM: Recruitment of First-Time, Tenure-Track Faculty Members

RRS: Recruitment of Rising Stars